Floatz logo

Lurbinectedin

Gastroenteropancreatic Neuroendocrine Tumor

PharmaMarSmall moleculePhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

34 Active assets in the Gastroenteropancreatic Neuroendocrine Tumor cohort.

Asset / SponsorPhaseRating
Oxodotreotide
National Cancer Institute (NCI)
Phase 4BBB
Octreotide Pamoate
Novartis Pharmaceuticals
Phase 3BB
Oxodotreotide
Vanderbilt-Ingram Cancer Center
Phase 4BB
EUDEMINE INJECTION
University of Maryland, Baltimore
Phase 4BB
Everolimus
RayzeBio, Inc.
Phase 3BB

View all 46 →

Same molecule, other indications

Lurbinectedin is also rated in:

Small-cell Lung CancerDormant
BBB
Indicative ·
72 / 100
View asset →
small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
small cell carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →